A randomised double-blind trial to assess the clinical effectiveness of Tranexamic acid after ICH and determine whether Tranexamic acid should be used in clinical practice.

TICH-3 is a pragmatic phase III prospective blinded randomised placebo-controlled trial to assess the clinical effectiveness of Tranexamic acid (TXA) after ICH and determine whether TXA should be used in clinical practice. Primary objective: To assess the effect of TXA on early death (≤ 7 days). Secondary objective: To assess the effect of TXA on dependency 6 months after ICH.